nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—FASN—ovarian cancer	0.568	1	CbGaD
Orlistat—PLA2G4A—Epirubicin—ovarian cancer	0.171	0.819	CbGbCtD
Orlistat—CYP3A4—Topotecan—ovarian cancer	0.0134	0.064	CbGbCtD
Orlistat—CYP3A4—Vinorelbine—ovarian cancer	0.00942	0.0451	CbGbCtD
Orlistat—CYP3A4—Paclitaxel—ovarian cancer	0.00662	0.0317	CbGbCtD
Orlistat—CYP3A4—Docetaxel—ovarian cancer	0.00478	0.0229	CbGbCtD
Orlistat—CYP3A4—Doxorubicin—ovarian cancer	0.00357	0.0171	CbGbCtD
Orlistat—LIPF—testis—ovarian cancer	0.00341	0.0455	CbGeAlD
Orlistat—FASN—Irinotecan—Topotecan—ovarian cancer	0.00292	1	CbGdCrCtD
Orlistat—PLA2G7—myometrium—ovarian cancer	0.00292	0.039	CbGeAlD
Orlistat—ABHD16A—myometrium—ovarian cancer	0.00274	0.0366	CbGeAlD
Orlistat—DAGLB—decidua—ovarian cancer	0.00268	0.0358	CbGeAlD
Orlistat—ABHD12—myometrium—ovarian cancer	0.00257	0.0343	CbGeAlD
Orlistat—DAGLA—testis—ovarian cancer	0.00219	0.0293	CbGeAlD
Orlistat—PLA2G7—decidua—ovarian cancer	0.00217	0.0289	CbGeAlD
Orlistat—FASN—myometrium—ovarian cancer	0.00216	0.0288	CbGeAlD
Orlistat—ABHD16A—uterine cervix—ovarian cancer	0.00213	0.0285	CbGeAlD
Orlistat—PLA2G7—endometrium—ovarian cancer	0.00206	0.0274	CbGeAlD
Orlistat—ABHD16A—decidua—ovarian cancer	0.00203	0.0271	CbGeAlD
Orlistat—ABHD12—uterine cervix—ovarian cancer	0.002	0.0267	CbGeAlD
Orlistat—ABHD16A—endometrium—ovarian cancer	0.00193	0.0258	CbGeAlD
Orlistat—DAGLB—female gonad—ovarian cancer	0.00192	0.0256	CbGeAlD
Orlistat—ABHD12—decidua—ovarian cancer	0.0019	0.0254	CbGeAlD
Orlistat—ABHD12—endometrium—ovarian cancer	0.00181	0.0241	CbGeAlD
Orlistat—DAGLB—testis—ovarian cancer	0.0017	0.0227	CbGeAlD
Orlistat—FASN—uterine cervix—ovarian cancer	0.00168	0.0224	CbGeAlD
Orlistat—PLA2G7—bone marrow—ovarian cancer	0.00161	0.0215	CbGeAlD
Orlistat—FASN—decidua—ovarian cancer	0.0016	0.0213	CbGeAlD
Orlistat—PLA2G7—female gonad—ovarian cancer	0.00155	0.0207	CbGeAlD
Orlistat—PLA2G7—vagina—ovarian cancer	0.00154	0.0206	CbGeAlD
Orlistat—ABHD16A—bone marrow—ovarian cancer	0.00151	0.0201	CbGeAlD
Orlistat—PNLIP—female reproductive system—ovarian cancer	0.0015	0.02	CbGeAlD
Orlistat—ABHD16A—female gonad—ovarian cancer	0.00145	0.0194	CbGeAlD
Orlistat—ABHD16A—vagina—ovarian cancer	0.00145	0.0193	CbGeAlD
Orlistat—FASN—uterus—ovarian cancer	0.0014	0.0187	CbGeAlD
Orlistat—ABHD12—female gonad—ovarian cancer	0.00136	0.0182	CbGeAlD
Orlistat—PNLIP—female gonad—ovarian cancer	0.00136	0.0182	CbGeAlD
Orlistat—ABHD12—vagina—ovarian cancer	0.00135	0.0181	CbGeAlD
Orlistat—ABHD16A—testis—ovarian cancer	0.00129	0.0172	CbGeAlD
Orlistat—DAGLB—lymph node—ovarian cancer	0.00123	0.0165	CbGeAlD
Orlistat—ABHD12—testis—ovarian cancer	0.00121	0.0161	CbGeAlD
Orlistat—FASN—female gonad—ovarian cancer	0.00114	0.0153	CbGeAlD
Orlistat—FASN—vagina—ovarian cancer	0.00114	0.0152	CbGeAlD
Orlistat—PLA2G4A—myometrium—ovarian cancer	0.00104	0.0138	CbGeAlD
Orlistat—FASN—testis—ovarian cancer	0.00101	0.0135	CbGeAlD
Orlistat—PLA2G7—lymph node—ovarian cancer	0.000996	0.0133	CbGeAlD
Orlistat—ABHD16A—lymph node—ovarian cancer	0.000935	0.0125	CbGeAlD
Orlistat—ABHD12—lymph node—ovarian cancer	0.000876	0.0117	CbGeAlD
Orlistat—PLA2G4A—uterine cervix—ovarian cancer	0.000806	0.0108	CbGeAlD
Orlistat—PLA2G4A—decidua—ovarian cancer	0.000768	0.0103	CbGeAlD
Orlistat—FASN—lymph node—ovarian cancer	0.000735	0.00981	CbGeAlD
Orlistat—PLA2G4A—endometrium—ovarian cancer	0.000729	0.00974	CbGeAlD
Orlistat—PLA2G4A—female reproductive system—ovarian cancer	0.000604	0.00806	CbGeAlD
Orlistat—PLA2G4A—bone marrow—ovarian cancer	0.00057	0.00761	CbGeAlD
Orlistat—PLA2G4A—female gonad—ovarian cancer	0.00055	0.00734	CbGeAlD
Orlistat—PLA2G4A—vagina—ovarian cancer	0.000546	0.00729	CbGeAlD
Orlistat—PLA2G4A—testis—ovarian cancer	0.000488	0.00651	CbGeAlD
Orlistat—PLA2G4A—lymph node—ovarian cancer	0.000353	0.00472	CbGeAlD
Orlistat—CYP3A4—female reproductive system—ovarian cancer	0.000199	0.00266	CbGeAlD
Orlistat—Vertigo—Paclitaxel—ovarian cancer	0.000111	0.00133	CcSEcCtD
Orlistat—Rash—Topotecan—ovarian cancer	0.000111	0.00132	CcSEcCtD
Orlistat—Hypersensitivity—Vinorelbine—ovarian cancer	0.000111	0.00132	CcSEcCtD
Orlistat—Dermatitis—Topotecan—ovarian cancer	0.000111	0.00132	CcSEcCtD
Orlistat—Headache—Topotecan—ovarian cancer	0.00011	0.00131	CcSEcCtD
Orlistat—Palpitations—Paclitaxel—ovarian cancer	0.00011	0.0013	CcSEcCtD
Orlistat—Vomiting—Melphalan—ovarian cancer	0.00011	0.0013	CcSEcCtD
Orlistat—Immune system disorder—Docetaxel—ovarian cancer	0.000109	0.0013	CcSEcCtD
Orlistat—Osteoarthritis—Doxorubicin—ovarian cancer	0.000109	0.0013	CcSEcCtD
Orlistat—Mediastinal disorder—Docetaxel—ovarian cancer	0.000109	0.0013	CcSEcCtD
Orlistat—Rash—Melphalan—ovarian cancer	0.000109	0.00129	CcSEcCtD
Orlistat—Dermatitis—Melphalan—ovarian cancer	0.000109	0.00129	CcSEcCtD
Orlistat—Cough—Paclitaxel—ovarian cancer	0.000108	0.00129	CcSEcCtD
Orlistat—Asthenia—Vinorelbine—ovarian cancer	0.000108	0.00128	CcSEcCtD
Orlistat—Dry skin—Epirubicin—ovarian cancer	0.000108	0.00128	CcSEcCtD
Orlistat—Abdominal pain upper—Epirubicin—ovarian cancer	0.000108	0.00128	CcSEcCtD
Orlistat—Convulsion—Paclitaxel—ovarian cancer	0.000108	0.00128	CcSEcCtD
Orlistat—Hypokalaemia—Epirubicin—ovarian cancer	0.000107	0.00128	CcSEcCtD
Orlistat—Alopecia—Docetaxel—ovarian cancer	0.000107	0.00127	CcSEcCtD
Orlistat—Pruritus—Vinorelbine—ovarian cancer	0.000107	0.00127	CcSEcCtD
Orlistat—Breast disorder—Epirubicin—ovarian cancer	0.000106	0.00127	CcSEcCtD
Orlistat—Mental disorder—Docetaxel—ovarian cancer	0.000106	0.00126	CcSEcCtD
Orlistat—Myalgia—Paclitaxel—ovarian cancer	0.000106	0.00126	CcSEcCtD
Orlistat—Chest pain—Paclitaxel—ovarian cancer	0.000106	0.00126	CcSEcCtD
Orlistat—Anxiety—Paclitaxel—ovarian cancer	0.000105	0.00125	CcSEcCtD
Orlistat—Malnutrition—Docetaxel—ovarian cancer	0.000105	0.00125	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000105	0.00125	CcSEcCtD
Orlistat—Nausea—Topotecan—ovarian cancer	0.000105	0.00124	CcSEcCtD
Orlistat—Discomfort—Paclitaxel—ovarian cancer	0.000104	0.00124	CcSEcCtD
Orlistat—Gastritis—Epirubicin—ovarian cancer	0.000104	0.00124	CcSEcCtD
Orlistat—Dry mouth—Paclitaxel—ovarian cancer	0.000103	0.00123	CcSEcCtD
Orlistat—Diarrhoea—Vinorelbine—ovarian cancer	0.000103	0.00123	CcSEcCtD
Orlistat—Dysgeusia—Docetaxel—ovarian cancer	0.000103	0.00123	CcSEcCtD
Orlistat—Abdominal distension—Epirubicin—ovarian cancer	0.000103	0.00122	CcSEcCtD
Orlistat—Nausea—Melphalan—ovarian cancer	0.000102	0.00122	CcSEcCtD
Orlistat—Influenza—Epirubicin—ovarian cancer	0.000102	0.00121	CcSEcCtD
Orlistat—Asthma—Epirubicin—ovarian cancer	0.000102	0.00121	CcSEcCtD
Orlistat—Back pain—Docetaxel—ovarian cancer	0.000102	0.00121	CcSEcCtD
Orlistat—Oedema—Paclitaxel—ovarian cancer	0.000101	0.0012	CcSEcCtD
Orlistat—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000101	0.0012	CcSEcCtD
Orlistat—Muscle spasms—Docetaxel—ovarian cancer	0.000101	0.0012	CcSEcCtD
Orlistat—Infection—Paclitaxel—ovarian cancer	0.000101	0.0012	CcSEcCtD
Orlistat—Dry skin—Doxorubicin—ovarian cancer	9.99e-05	0.00119	CcSEcCtD
Orlistat—Pancreatitis—Epirubicin—ovarian cancer	9.98e-05	0.00119	CcSEcCtD
Orlistat—Dizziness—Vinorelbine—ovarian cancer	9.96e-05	0.00118	CcSEcCtD
Orlistat—Abdominal pain upper—Doxorubicin—ovarian cancer	9.96e-05	0.00118	CcSEcCtD
Orlistat—Nervous system disorder—Paclitaxel—ovarian cancer	9.93e-05	0.00118	CcSEcCtD
Orlistat—Hypokalaemia—Doxorubicin—ovarian cancer	9.92e-05	0.00118	CcSEcCtD
Orlistat—Breast disorder—Doxorubicin—ovarian cancer	9.85e-05	0.00117	CcSEcCtD
Orlistat—Skin disorder—Paclitaxel—ovarian cancer	9.84e-05	0.00117	CcSEcCtD
Orlistat—Hyperhidrosis—Paclitaxel—ovarian cancer	9.79e-05	0.00116	CcSEcCtD
Orlistat—Gastritis—Doxorubicin—ovarian cancer	9.65e-05	0.00115	CcSEcCtD
Orlistat—Vomiting—Vinorelbine—ovarian cancer	9.57e-05	0.00114	CcSEcCtD
Orlistat—Rash—Vinorelbine—ovarian cancer	9.49e-05	0.00113	CcSEcCtD
Orlistat—Dermatitis—Vinorelbine—ovarian cancer	9.49e-05	0.00113	CcSEcCtD
Orlistat—Abdominal distension—Doxorubicin—ovarian cancer	9.48e-05	0.00113	CcSEcCtD
Orlistat—Upper respiratory tract infection—Epirubicin—ovarian cancer	9.46e-05	0.00113	CcSEcCtD
Orlistat—Headache—Vinorelbine—ovarian cancer	9.43e-05	0.00112	CcSEcCtD
Orlistat—Influenza—Doxorubicin—ovarian cancer	9.42e-05	0.00112	CcSEcCtD
Orlistat—Asthma—Doxorubicin—ovarian cancer	9.42e-05	0.00112	CcSEcCtD
Orlistat—Palpitations—Docetaxel—ovarian cancer	9.3e-05	0.00111	CcSEcCtD
Orlistat—Pancreatitis—Doxorubicin—ovarian cancer	9.24e-05	0.0011	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	9.23e-05	0.0011	CcSEcCtD
Orlistat—Cough—Docetaxel—ovarian cancer	9.18e-05	0.00109	CcSEcCtD
Orlistat—Insomnia—Paclitaxel—ovarian cancer	9.16e-05	0.00109	CcSEcCtD
Orlistat—Convulsion—Docetaxel—ovarian cancer	9.11e-05	0.00108	CcSEcCtD
Orlistat—Paraesthesia—Paclitaxel—ovarian cancer	9.09e-05	0.00108	CcSEcCtD
Orlistat—Infestation NOS—Epirubicin—ovarian cancer	9.08e-05	0.00108	CcSEcCtD
Orlistat—Infestation—Epirubicin—ovarian cancer	9.08e-05	0.00108	CcSEcCtD
Orlistat—Chest pain—Docetaxel—ovarian cancer	8.95e-05	0.00107	CcSEcCtD
Orlistat—Myalgia—Docetaxel—ovarian cancer	8.95e-05	0.00107	CcSEcCtD
Orlistat—Nausea—Vinorelbine—ovarian cancer	8.94e-05	0.00106	CcSEcCtD
Orlistat—Renal failure—Epirubicin—ovarian cancer	8.92e-05	0.00106	CcSEcCtD
Orlistat—Dyspepsia—Paclitaxel—ovarian cancer	8.92e-05	0.00106	CcSEcCtD
Orlistat—Neuropathy peripheral—Epirubicin—ovarian cancer	8.9e-05	0.00106	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	8.89e-05	0.00106	CcSEcCtD
Orlistat—Urinary tract infection—Epirubicin—ovarian cancer	8.82e-05	0.00105	CcSEcCtD
Orlistat—Decreased appetite—Paclitaxel—ovarian cancer	8.8e-05	0.00105	CcSEcCtD
Orlistat—Dry mouth—Docetaxel—ovarian cancer	8.76e-05	0.00104	CcSEcCtD
Orlistat—Upper respiratory tract infection—Doxorubicin—ovarian cancer	8.76e-05	0.00104	CcSEcCtD
Orlistat—Gastrointestinal disorder—Paclitaxel—ovarian cancer	8.74e-05	0.00104	CcSEcCtD
Orlistat—Fatigue—Paclitaxel—ovarian cancer	8.73e-05	0.00104	CcSEcCtD
Orlistat—Pain—Paclitaxel—ovarian cancer	8.66e-05	0.00103	CcSEcCtD
Orlistat—Hepatobiliary disease—Epirubicin—ovarian cancer	8.59e-05	0.00102	CcSEcCtD
Orlistat—Oedema—Docetaxel—ovarian cancer	8.58e-05	0.00102	CcSEcCtD
Orlistat—Anaphylactic shock—Docetaxel—ovarian cancer	8.58e-05	0.00102	CcSEcCtD
Orlistat—Infection—Docetaxel—ovarian cancer	8.53e-05	0.00101	CcSEcCtD
Orlistat—Sinusitis—Epirubicin—ovarian cancer	8.52e-05	0.00101	CcSEcCtD
Orlistat—Nervous system disorder—Docetaxel—ovarian cancer	8.42e-05	0.001	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—ovarian cancer	8.4e-05	0.000999	CcSEcCtD
Orlistat—Infestation—Doxorubicin—ovarian cancer	8.4e-05	0.000999	CcSEcCtD
Orlistat—Feeling abnormal—Paclitaxel—ovarian cancer	8.35e-05	0.000993	CcSEcCtD
Orlistat—Skin disorder—Docetaxel—ovarian cancer	8.34e-05	0.000992	CcSEcCtD
Orlistat—Gastrointestinal pain—Paclitaxel—ovarian cancer	8.28e-05	0.000985	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—ovarian cancer	8.26e-05	0.000982	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—ovarian cancer	8.23e-05	0.000979	CcSEcCtD
Orlistat—Haemoglobin—Epirubicin—ovarian cancer	8.19e-05	0.000974	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—ovarian cancer	8.17e-05	0.000971	CcSEcCtD
Orlistat—Haemorrhage—Epirubicin—ovarian cancer	8.15e-05	0.000969	CcSEcCtD
Orlistat—Hepatitis—Epirubicin—ovarian cancer	8.15e-05	0.000969	CcSEcCtD
Orlistat—Pharyngitis—Epirubicin—ovarian cancer	8.09e-05	0.000962	CcSEcCtD
Orlistat—Urinary tract disorder—Epirubicin—ovarian cancer	8.05e-05	0.000957	CcSEcCtD
Orlistat—Urticaria—Paclitaxel—ovarian cancer	8.05e-05	0.000957	CcSEcCtD
Orlistat—Oedema peripheral—Epirubicin—ovarian cancer	8.03e-05	0.000955	CcSEcCtD
Orlistat—Abdominal pain—Paclitaxel—ovarian cancer	8.01e-05	0.000952	CcSEcCtD
Orlistat—Body temperature increased—Paclitaxel—ovarian cancer	8.01e-05	0.000952	CcSEcCtD
Orlistat—Urethral disorder—Epirubicin—ovarian cancer	7.99e-05	0.00095	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—ovarian cancer	7.94e-05	0.000945	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—ovarian cancer	7.88e-05	0.000937	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Docetaxel—ovarian cancer	7.82e-05	0.00093	CcSEcCtD
Orlistat—Insomnia—Docetaxel—ovarian cancer	7.76e-05	0.000923	CcSEcCtD
Orlistat—Paraesthesia—Docetaxel—ovarian cancer	7.71e-05	0.000917	CcSEcCtD
Orlistat—Haemoglobin—Doxorubicin—ovarian cancer	7.58e-05	0.000901	CcSEcCtD
Orlistat—Dyspepsia—Docetaxel—ovarian cancer	7.56e-05	0.000899	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—ovarian cancer	7.54e-05	0.000897	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—ovarian cancer	7.54e-05	0.000897	CcSEcCtD
Orlistat—Pharyngitis—Doxorubicin—ovarian cancer	7.48e-05	0.00089	CcSEcCtD
Orlistat—Decreased appetite—Docetaxel—ovarian cancer	7.46e-05	0.000888	CcSEcCtD
Orlistat—Hypersensitivity—Paclitaxel—ovarian cancer	7.46e-05	0.000887	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—ovarian cancer	7.45e-05	0.000886	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—ovarian cancer	7.43e-05	0.000884	CcSEcCtD
Orlistat—Gastrointestinal disorder—Docetaxel—ovarian cancer	7.41e-05	0.000881	CcSEcCtD
Orlistat—Fatigue—Docetaxel—ovarian cancer	7.4e-05	0.00088	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—ovarian cancer	7.39e-05	0.000879	CcSEcCtD
Orlistat—Immune system disorder—Epirubicin—ovarian cancer	7.36e-05	0.000876	CcSEcCtD
Orlistat—Mediastinal disorder—Epirubicin—ovarian cancer	7.34e-05	0.000874	CcSEcCtD
Orlistat—Pain—Docetaxel—ovarian cancer	7.34e-05	0.000873	CcSEcCtD
Orlistat—Asthenia—Paclitaxel—ovarian cancer	7.27e-05	0.000864	CcSEcCtD
Orlistat—Alopecia—Epirubicin—ovarian cancer	7.2e-05	0.000857	CcSEcCtD
Orlistat—Pruritus—Paclitaxel—ovarian cancer	7.17e-05	0.000852	CcSEcCtD
Orlistat—Mental disorder—Epirubicin—ovarian cancer	7.14e-05	0.000849	CcSEcCtD
Orlistat—Malnutrition—Epirubicin—ovarian cancer	7.09e-05	0.000844	CcSEcCtD
Orlistat—Feeling abnormal—Docetaxel—ovarian cancer	7.07e-05	0.000841	CcSEcCtD
Orlistat—Gastrointestinal pain—Docetaxel—ovarian cancer	7.02e-05	0.000835	CcSEcCtD
Orlistat—Flatulence—Epirubicin—ovarian cancer	6.99e-05	0.000831	CcSEcCtD
Orlistat—Dysgeusia—Epirubicin—ovarian cancer	6.95e-05	0.000826	CcSEcCtD
Orlistat—Diarrhoea—Paclitaxel—ovarian cancer	6.93e-05	0.000824	CcSEcCtD
Orlistat—Back pain—Epirubicin—ovarian cancer	6.86e-05	0.000816	CcSEcCtD
Orlistat—Muscle spasms—Epirubicin—ovarian cancer	6.82e-05	0.000811	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—ovarian cancer	6.81e-05	0.00081	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—ovarian cancer	6.8e-05	0.000808	CcSEcCtD
Orlistat—Abdominal pain—Docetaxel—ovarian cancer	6.79e-05	0.000807	CcSEcCtD
Orlistat—Body temperature increased—Docetaxel—ovarian cancer	6.79e-05	0.000807	CcSEcCtD
Orlistat—Dizziness—Paclitaxel—ovarian cancer	6.7e-05	0.000797	CcSEcCtD
Orlistat—Vision blurred—Epirubicin—ovarian cancer	6.69e-05	0.000795	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—ovarian cancer	6.66e-05	0.000793	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—ovarian cancer	6.61e-05	0.000786	CcSEcCtD
Orlistat—Ill-defined disorder—Epirubicin—ovarian cancer	6.58e-05	0.000783	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—ovarian cancer	6.56e-05	0.000781	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—ovarian cancer	6.47e-05	0.000769	CcSEcCtD
Orlistat—Vomiting—Paclitaxel—ovarian cancer	6.44e-05	0.000766	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—ovarian cancer	6.43e-05	0.000765	CcSEcCtD
Orlistat—Malaise—Epirubicin—ovarian cancer	6.4e-05	0.000761	CcSEcCtD
Orlistat—Rash—Paclitaxel—ovarian cancer	6.39e-05	0.000759	CcSEcCtD
Orlistat—Dermatitis—Paclitaxel—ovarian cancer	6.38e-05	0.000759	CcSEcCtD
Orlistat—Vertigo—Epirubicin—ovarian cancer	6.37e-05	0.000758	CcSEcCtD
Orlistat—Back pain—Doxorubicin—ovarian cancer	6.35e-05	0.000755	CcSEcCtD
Orlistat—Headache—Paclitaxel—ovarian cancer	6.34e-05	0.000755	CcSEcCtD
Orlistat—Hypersensitivity—Docetaxel—ovarian cancer	6.32e-05	0.000752	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—ovarian cancer	6.31e-05	0.000751	CcSEcCtD
Orlistat—Palpitations—Epirubicin—ovarian cancer	6.27e-05	0.000746	CcSEcCtD
Orlistat—Cough—Epirubicin—ovarian cancer	6.19e-05	0.000736	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—ovarian cancer	6.19e-05	0.000736	CcSEcCtD
Orlistat—Asthenia—Docetaxel—ovarian cancer	6.16e-05	0.000733	CcSEcCtD
Orlistat—Convulsion—Epirubicin—ovarian cancer	6.15e-05	0.000731	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—ovarian cancer	6.09e-05	0.000724	CcSEcCtD
Orlistat—Pruritus—Docetaxel—ovarian cancer	6.07e-05	0.000722	CcSEcCtD
Orlistat—Chest pain—Epirubicin—ovarian cancer	6.04e-05	0.000718	CcSEcCtD
Orlistat—Myalgia—Epirubicin—ovarian cancer	6.04e-05	0.000718	CcSEcCtD
Orlistat—Anxiety—Epirubicin—ovarian cancer	6.02e-05	0.000716	CcSEcCtD
Orlistat—Nausea—Paclitaxel—ovarian cancer	6.02e-05	0.000715	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	6e-05	0.000713	CcSEcCtD
Orlistat—Discomfort—Epirubicin—ovarian cancer	5.97e-05	0.00071	CcSEcCtD
Orlistat—Malaise—Doxorubicin—ovarian cancer	5.92e-05	0.000704	CcSEcCtD
Orlistat—Dry mouth—Epirubicin—ovarian cancer	5.91e-05	0.000703	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—ovarian cancer	5.9e-05	0.000701	CcSEcCtD
Orlistat—Diarrhoea—Docetaxel—ovarian cancer	5.87e-05	0.000699	CcSEcCtD
Orlistat—Palpitations—Doxorubicin—ovarian cancer	5.8e-05	0.00069	CcSEcCtD
Orlistat—Anaphylactic shock—Epirubicin—ovarian cancer	5.79e-05	0.000689	CcSEcCtD
Orlistat—Oedema—Epirubicin—ovarian cancer	5.79e-05	0.000689	CcSEcCtD
Orlistat—Infection—Epirubicin—ovarian cancer	5.75e-05	0.000684	CcSEcCtD
Orlistat—Cough—Doxorubicin—ovarian cancer	5.73e-05	0.000681	CcSEcCtD
Orlistat—Convulsion—Doxorubicin—ovarian cancer	5.69e-05	0.000676	CcSEcCtD
Orlistat—Nervous system disorder—Epirubicin—ovarian cancer	5.68e-05	0.000675	CcSEcCtD
Orlistat—Dizziness—Docetaxel—ovarian cancer	5.68e-05	0.000675	CcSEcCtD
Orlistat—Skin disorder—Epirubicin—ovarian cancer	5.62e-05	0.000669	CcSEcCtD
Orlistat—Hyperhidrosis—Epirubicin—ovarian cancer	5.6e-05	0.000666	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—ovarian cancer	5.59e-05	0.000665	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—ovarian cancer	5.59e-05	0.000665	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—ovarian cancer	5.57e-05	0.000662	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.55e-05	0.00066	CcSEcCtD
Orlistat—Discomfort—Doxorubicin—ovarian cancer	5.52e-05	0.000657	CcSEcCtD
Orlistat—Dry mouth—Doxorubicin—ovarian cancer	5.47e-05	0.00065	CcSEcCtD
Orlistat—Vomiting—Docetaxel—ovarian cancer	5.46e-05	0.000649	CcSEcCtD
Orlistat—Rash—Docetaxel—ovarian cancer	5.41e-05	0.000644	CcSEcCtD
Orlistat—Dermatitis—Docetaxel—ovarian cancer	5.41e-05	0.000643	CcSEcCtD
Orlistat—Headache—Docetaxel—ovarian cancer	5.38e-05	0.00064	CcSEcCtD
Orlistat—Oedema—Doxorubicin—ovarian cancer	5.36e-05	0.000637	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—ovarian cancer	5.36e-05	0.000637	CcSEcCtD
Orlistat—Infection—Doxorubicin—ovarian cancer	5.32e-05	0.000633	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.28e-05	0.000627	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—ovarian cancer	5.25e-05	0.000625	CcSEcCtD
Orlistat—Insomnia—Epirubicin—ovarian cancer	5.24e-05	0.000623	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—ovarian cancer	5.2e-05	0.000619	CcSEcCtD
Orlistat—Paraesthesia—Epirubicin—ovarian cancer	5.2e-05	0.000618	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—ovarian cancer	5.18e-05	0.000616	CcSEcCtD
Orlistat—Nausea—Docetaxel—ovarian cancer	5.1e-05	0.000606	CcSEcCtD
Orlistat—Dyspepsia—Epirubicin—ovarian cancer	5.1e-05	0.000606	CcSEcCtD
Orlistat—Decreased appetite—Epirubicin—ovarian cancer	5.03e-05	0.000599	CcSEcCtD
Orlistat—Gastrointestinal disorder—Epirubicin—ovarian cancer	5e-05	0.000595	CcSEcCtD
Orlistat—Fatigue—Epirubicin—ovarian cancer	4.99e-05	0.000594	CcSEcCtD
Orlistat—Pain—Epirubicin—ovarian cancer	4.95e-05	0.000589	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.88e-05	0.000581	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—ovarian cancer	4.85e-05	0.000576	CcSEcCtD
Orlistat—Paraesthesia—Doxorubicin—ovarian cancer	4.81e-05	0.000572	CcSEcCtD
Orlistat—Feeling abnormal—Epirubicin—ovarian cancer	4.77e-05	0.000567	CcSEcCtD
Orlistat—Gastrointestinal pain—Epirubicin—ovarian cancer	4.73e-05	0.000563	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—ovarian cancer	4.72e-05	0.000561	CcSEcCtD
Orlistat—Decreased appetite—Doxorubicin—ovarian cancer	4.66e-05	0.000554	CcSEcCtD
Orlistat—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.63e-05	0.00055	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—ovarian cancer	4.62e-05	0.000549	CcSEcCtD
Orlistat—Urticaria—Epirubicin—ovarian cancer	4.6e-05	0.000547	CcSEcCtD
Orlistat—Pain—Doxorubicin—ovarian cancer	4.58e-05	0.000545	CcSEcCtD
Orlistat—Abdominal pain—Epirubicin—ovarian cancer	4.58e-05	0.000544	CcSEcCtD
Orlistat—Body temperature increased—Epirubicin—ovarian cancer	4.58e-05	0.000544	CcSEcCtD
Orlistat—Feeling abnormal—Doxorubicin—ovarian cancer	4.41e-05	0.000525	CcSEcCtD
Orlistat—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.38e-05	0.000521	CcSEcCtD
Orlistat—Hypersensitivity—Epirubicin—ovarian cancer	4.27e-05	0.000507	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—ovarian cancer	4.26e-05	0.000506	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—ovarian cancer	4.24e-05	0.000504	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—ovarian cancer	4.24e-05	0.000504	CcSEcCtD
Orlistat—Asthenia—Epirubicin—ovarian cancer	4.15e-05	0.000494	CcSEcCtD
Orlistat—Pruritus—Epirubicin—ovarian cancer	4.1e-05	0.000487	CcSEcCtD
Orlistat—Diarrhoea—Epirubicin—ovarian cancer	3.96e-05	0.000471	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—ovarian cancer	3.95e-05	0.000469	CcSEcCtD
Orlistat—Asthenia—Doxorubicin—ovarian cancer	3.84e-05	0.000457	CcSEcCtD
Orlistat—Dizziness—Epirubicin—ovarian cancer	3.83e-05	0.000455	CcSEcCtD
Orlistat—Pruritus—Doxorubicin—ovarian cancer	3.79e-05	0.000451	CcSEcCtD
Orlistat—Vomiting—Epirubicin—ovarian cancer	3.68e-05	0.000438	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—ovarian cancer	3.67e-05	0.000436	CcSEcCtD
Orlistat—Rash—Epirubicin—ovarian cancer	3.65e-05	0.000434	CcSEcCtD
Orlistat—Dermatitis—Epirubicin—ovarian cancer	3.65e-05	0.000434	CcSEcCtD
Orlistat—Headache—Epirubicin—ovarian cancer	3.63e-05	0.000431	CcSEcCtD
Orlistat—Dizziness—Doxorubicin—ovarian cancer	3.54e-05	0.000421	CcSEcCtD
Orlistat—Nausea—Epirubicin—ovarian cancer	3.44e-05	0.000409	CcSEcCtD
Orlistat—Vomiting—Doxorubicin—ovarian cancer	3.41e-05	0.000405	CcSEcCtD
Orlistat—Rash—Doxorubicin—ovarian cancer	3.38e-05	0.000402	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—ovarian cancer	3.37e-05	0.000401	CcSEcCtD
Orlistat—Headache—Doxorubicin—ovarian cancer	3.36e-05	0.000399	CcSEcCtD
Orlistat—Nausea—Doxorubicin—ovarian cancer	3.18e-05	0.000378	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—PPP1CC—ovarian cancer	2.61e-05	0.000427	CbGpPWpGaD
Orlistat—PNLIP—Disease—CDKN1B—ovarian cancer	2.61e-05	0.000426	CbGpPWpGaD
Orlistat—FASN—Disease—APC—ovarian cancer	2.57e-05	0.00042	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—APC—ovarian cancer	2.54e-05	0.000415	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CG—ovarian cancer	2.54e-05	0.000415	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.52e-05	0.000412	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—CAV1—ovarian cancer	2.5e-05	0.000408	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	2.5e-05	0.000408	CbGpPWpGaD
Orlistat—PNLIP—Disease—CTNNB1—ovarian cancer	2.47e-05	0.000403	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PIK3CA—ovarian cancer	2.43e-05	0.000396	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PIK3CA—ovarian cancer	2.43e-05	0.000396	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTEN—ovarian cancer	2.4e-05	0.000393	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ERBB2—ovarian cancer	2.38e-05	0.000389	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ERBB2—ovarian cancer	2.38e-05	0.000389	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	2.38e-05	0.000388	CbGpPWpGaD
Orlistat—FASN—Metabolism—CAV1—ovarian cancer	2.36e-05	0.000386	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CB—ovarian cancer	2.35e-05	0.000384	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MTOR—ovarian cancer	2.35e-05	0.000384	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MTOR—ovarian cancer	2.35e-05	0.000384	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CB—ovarian cancer	2.35e-05	0.000384	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CB—ovarian cancer	2.33e-05	0.000381	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.32e-05	0.000379	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CG—ovarian cancer	2.28e-05	0.000372	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.27e-05	0.000372	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCL8—ovarian cancer	2.26e-05	0.000369	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCL8—ovarian cancer	2.26e-05	0.000369	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CD—ovarian cancer	2.26e-05	0.000369	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.26e-05	0.000369	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HRAS—ovarian cancer	2.24e-05	0.000367	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—HRAS—ovarian cancer	2.24e-05	0.000367	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.24e-05	0.000366	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CD—ovarian cancer	2.23e-05	0.000365	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CDKN1B—ovarian cancer	2.21e-05	0.00036	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CDKN1B—ovarian cancer	2.21e-05	0.00036	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AKT1—ovarian cancer	2.18e-05	0.000357	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AKT1—ovarian cancer	2.18e-05	0.000357	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CASP3—ovarian cancer	2.16e-05	0.000353	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CASP3—ovarian cancer	2.16e-05	0.000353	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2—ovarian cancer	2.16e-05	0.000353	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2—ovarian cancer	2.16e-05	0.000353	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CG—ovarian cancer	2.15e-05	0.000351	CbGpPWpGaD
Orlistat—PNLIP—Disease—STAT3—ovarian cancer	2.15e-05	0.000351	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6—ovarian cancer	2.15e-05	0.000351	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6—ovarian cancer	2.15e-05	0.000351	CbGpPWpGaD
Orlistat—PNLIP—Disease—NRAS—ovarian cancer	2.14e-05	0.00035	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	2.13e-05	0.000348	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCND1—ovarian cancer	2.1e-05	0.000344	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCND1—ovarian cancer	2.1e-05	0.000344	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	2.1e-05	0.000343	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—YAP1—ovarian cancer	2.09e-05	0.000342	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CTNNB1—ovarian cancer	2.08e-05	0.000341	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CTNNB1—ovarian cancer	2.08e-05	0.000341	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.07e-05	0.000339	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	2.06e-05	0.000337	CbGpPWpGaD
Orlistat—PNLIP—Disease—MAPK3—ovarian cancer	2.05e-05	0.000336	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MMP9—ovarian cancer	2.04e-05	0.000334	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MMP9—ovarian cancer	2.04e-05	0.000334	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTEN—ovarian cancer	2.03e-05	0.000332	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTEN—ovarian cancer	2.03e-05	0.000332	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTEN—ovarian cancer	2.01e-05	0.000329	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CD—ovarian cancer	2e-05	0.000327	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—ovarian cancer	2e-05	0.000326	CbGpPWpGaD
Orlistat—FASN—Disease—ERBB2—ovarian cancer	1.99e-05	0.000326	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKT1—ovarian cancer	1.98e-05	0.000324	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AKT1—ovarian cancer	1.98e-05	0.000324	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HDAC6—ovarian cancer	1.98e-05	0.000323	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ERBB2—ovarian cancer	1.97e-05	0.000322	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CB—ovarian cancer	1.97e-05	0.000322	CbGpPWpGaD
Orlistat—FASN—Disease—MTOR—ovarian cancer	1.97e-05	0.000322	CbGpPWpGaD
Orlistat—PNLIP—Disease—MAPK1—ovarian cancer	1.95e-05	0.000319	CbGpPWpGaD
Orlistat—PNLIP—Disease—EGFR—ovarian cancer	1.95e-05	0.000319	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PPP2R1A—ovarian cancer	1.95e-05	0.000319	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CB—ovarian cancer	1.95e-05	0.000318	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MTOR—ovarian cancer	1.95e-05	0.000318	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.89e-05	0.000309	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CD—ovarian cancer	1.89e-05	0.000309	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCL8—ovarian cancer	1.87e-05	0.000306	CbGpPWpGaD
Orlistat—FASN—Disease—CDKN1B—ovarian cancer	1.85e-05	0.000302	CbGpPWpGaD
Orlistat—PNLIP—Disease—KRAS—ovarian cancer	1.85e-05	0.000302	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—ovarian cancer	1.83e-05	0.0003	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—ovarian cancer	1.83e-05	0.0003	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CDKN1B—ovarian cancer	1.83e-05	0.000299	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.82e-05	0.000298	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—STAT3—ovarian cancer	1.82e-05	0.000297	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—STAT3—ovarian cancer	1.82e-05	0.000297	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NRAS—ovarian cancer	1.81e-05	0.000296	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NRAS—ovarian cancer	1.81e-05	0.000296	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CASP3—ovarian cancer	1.79e-05	0.000293	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2—ovarian cancer	1.79e-05	0.000292	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—YAP1—ovarian cancer	1.75e-05	0.000286	CbGpPWpGaD
Orlistat—FASN—Disease—CTNNB1—ovarian cancer	1.74e-05	0.000285	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CB—ovarian cancer	1.74e-05	0.000285	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCND1—ovarian cancer	1.74e-05	0.000285	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK3—ovarian cancer	1.74e-05	0.000284	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK3—ovarian cancer	1.74e-05	0.000284	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CTNNB1—ovarian cancer	1.73e-05	0.000282	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—XIAP—ovarian cancer	1.72e-05	0.00028	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—FASN—ovarian cancer	1.71e-05	0.000279	CbGpPWpGaD
Orlistat—FASN—Disease—PTEN—ovarian cancer	1.7e-05	0.000278	CbGpPWpGaD
Orlistat—PNLIP—Disease—PIK3CA—ovarian cancer	1.7e-05	0.000277	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—ovarian cancer	1.69e-05	0.000277	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—ovarian cancer	1.69e-05	0.000276	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—ovarian cancer	1.69e-05	0.000276	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	1.68e-05	0.000275	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTEN—ovarian cancer	1.68e-05	0.000275	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC5A5—ovarian cancer	1.68e-05	0.000274	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SMARCA4—ovarian cancer	1.67e-05	0.000273	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK1—ovarian cancer	1.65e-05	0.00027	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK1—ovarian cancer	1.65e-05	0.00027	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—ovarian cancer	1.65e-05	0.00027	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—ovarian cancer	1.65e-05	0.00027	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CB—ovarian cancer	1.65e-05	0.000269	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EREG—ovarian cancer	1.63e-05	0.000267	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC2A1—ovarian cancer	1.62e-05	0.000265	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2—ovarian cancer	1.6e-05	0.000262	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.59e-05	0.000259	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—ovarian cancer	1.57e-05	0.000256	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—ovarian cancer	1.56e-05	0.000255	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—ovarian cancer	1.56e-05	0.000255	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP1B1—ovarian cancer	1.55e-05	0.000254	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PGR—ovarian cancer	1.53e-05	0.00025	CbGpPWpGaD
Orlistat—FASN—Disease—STAT3—ovarian cancer	1.52e-05	0.000248	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—ovarian cancer	1.52e-05	0.000248	CbGpPWpGaD
Orlistat—FASN—Disease—NRAS—ovarian cancer	1.52e-05	0.000248	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—ovarian cancer	1.5e-05	0.000246	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NRAS—ovarian cancer	1.5e-05	0.000245	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—ovarian cancer	1.5e-05	0.000245	CbGpPWpGaD
Orlistat—FASN—Disease—MAPK3—ovarian cancer	1.45e-05	0.000237	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK3—ovarian cancer	1.44e-05	0.000235	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CA—ovarian cancer	1.43e-05	0.000234	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CA—ovarian cancer	1.43e-05	0.000234	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTEN—ovarian cancer	1.42e-05	0.000233	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PARP1—ovarian cancer	1.42e-05	0.000232	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—ovarian cancer	1.42e-05	0.000232	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—ovarian cancer	1.41e-05	0.000231	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—ovarian cancer	1.4e-05	0.000229	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—ovarian cancer	1.39e-05	0.000227	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—ovarian cancer	1.39e-05	0.000227	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—ovarian cancer	1.38e-05	0.000226	CbGpPWpGaD
Orlistat—FASN—Disease—MAPK1—ovarian cancer	1.38e-05	0.000226	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—ovarian cancer	1.38e-05	0.000226	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPP2R1A—ovarian cancer	1.38e-05	0.000225	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.37e-05	0.000224	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK1—ovarian cancer	1.37e-05	0.000224	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—ovarian cancer	1.37e-05	0.000224	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—ovarian cancer	1.36e-05	0.000222	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6ST—ovarian cancer	1.36e-05	0.000222	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NRAS—ovarian cancer	1.34e-05	0.00022	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—ovarian cancer	1.33e-05	0.000217	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—ovarian cancer	1.33e-05	0.000217	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CG—ovarian cancer	1.31e-05	0.000213	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—ovarian cancer	1.31e-05	0.000213	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NME2—ovarian cancer	1.3e-05	0.000212	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—ovarian cancer	1.29e-05	0.000211	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MAPK3—ovarian cancer	1.29e-05	0.00021	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ABCB1—ovarian cancer	1.28e-05	0.000209	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—ovarian cancer	1.27e-05	0.000207	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—ovarian cancer	1.27e-05	0.000207	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TYMS—ovarian cancer	1.26e-05	0.000205	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MAPK1—ovarian cancer	1.23e-05	0.0002	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—ovarian cancer	1.2e-05	0.000196	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—ovarian cancer	1.19e-05	0.000194	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—ovarian cancer	1.17e-05	0.000191	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—ovarian cancer	1.17e-05	0.000191	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—ovarian cancer	1.16e-05	0.00019	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—ovarian cancer	1.16e-05	0.000189	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PPP2R1A—ovarian cancer	1.15e-05	0.000188	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—ovarian cancer	1.15e-05	0.000188	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CD—ovarian cancer	1.15e-05	0.000188	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—ovarian cancer	1.11e-05	0.000181	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—ovarian cancer	1.1e-05	0.000179	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—ovarian cancer	1.06e-05	0.000174	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—ovarian cancer	1.06e-05	0.000174	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—ovarian cancer	1.05e-05	0.000172	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—ovarian cancer	1.03e-05	0.000168	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CAV1—ovarian cancer	1.01e-05	0.000166	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—ovarian cancer	1e-05	0.000164	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CB—ovarian cancer	1e-05	0.000164	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—ovarian cancer	9.84e-06	0.000161	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—ovarian cancer	9.8e-06	0.00016	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—ovarian cancer	9.7e-06	0.000158	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.68e-06	0.000158	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL8—ovarian cancer	9.62e-06	0.000157	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CG—ovarian cancer	9.23e-06	0.000151	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—ovarian cancer	9.19e-06	0.00015	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TERT—ovarian cancer	9.16e-06	0.00015	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—ovarian cancer	8.68e-06	0.000142	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CAV1—ovarian cancer	8.47e-06	0.000138	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYTB—ovarian cancer	8.36e-06	0.000137	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—ovarian cancer	8.2e-06	0.000134	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ESR1—ovarian cancer	8.16e-06	0.000133	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CD—ovarian cancer	8.11e-06	0.000133	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6ST—ovarian cancer	8.03e-06	0.000131	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APC—ovarian cancer	7.72e-06	0.000126	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CG—ovarian cancer	7.72e-06	0.000126	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—NRAS—ovarian cancer	7.72e-06	0.000126	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAPK3—ovarian cancer	7.39e-06	0.000121	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPP1CC—ovarian cancer	7.31e-06	0.000119	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BRIP1—ovarian cancer	7.31e-06	0.000119	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CB—ovarian cancer	7.07e-06	0.000116	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAPK1—ovarian cancer	7.03e-06	0.000115	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—ovarian cancer	7.03e-06	0.000115	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CD—ovarian cancer	6.78e-06	0.000111	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—ovarian cancer	6.64e-06	0.000109	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTEN—ovarian cancer	6.11e-06	9.99e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—ovarian cancer	6.1e-06	9.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB2—ovarian cancer	5.99e-06	9.79e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MTOR—ovarian cancer	5.91e-06	9.66e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CB—ovarian cancer	5.91e-06	9.66e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL8—ovarian cancer	5.68e-06	9.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—ovarian cancer	5.64e-06	9.23e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1B—ovarian cancer	5.55e-06	9.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—ovarian cancer	5.44e-06	8.89e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—ovarian cancer	5.43e-06	8.87e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—ovarian cancer	5.4e-06	8.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—ovarian cancer	5.29e-06	8.65e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNB1—ovarian cancer	5.24e-06	8.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—ovarian cancer	5.14e-06	8.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTEN—ovarian cancer	5.11e-06	8.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—ovarian cancer	4.98e-06	8.15e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—YAP1—ovarian cancer	4.9e-06	8.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—ovarian cancer	4.61e-06	7.54e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—ovarian cancer	4.57e-06	7.47e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRAS—ovarian cancer	4.56e-06	7.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK3—ovarian cancer	4.36e-06	7.13e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—ovarian cancer	4.31e-06	7.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—ovarian cancer	4.25e-06	6.94e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK1—ovarian cancer	4.15e-06	6.79e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—ovarian cancer	4.15e-06	6.79e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—FASN—ovarian cancer	4e-06	6.53e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.93e-06	6.43e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—ovarian cancer	3.92e-06	6.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.8e-06	6.21e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1B1—ovarian cancer	3.64e-06	5.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—ovarian cancer	3.6e-06	5.89e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—ovarian cancer	3.52e-06	5.75e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—ovarian cancer	3.49e-06	5.7e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—ovarian cancer	3.33e-06	5.45e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.23e-06	5.28e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—ovarian cancer	3.19e-06	5.22e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCB1—ovarian cancer	3e-06	4.9e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TYMS—ovarian cancer	2.94e-06	4.81e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—ovarian cancer	2.94e-06	4.81e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CAV1—ovarian cancer	2.37e-06	3.88e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.16e-06	3.53e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.9e-06	3.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.66e-06	2.71e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTEN—ovarian cancer	1.43e-06	2.34e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.01e-06	1.65e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—ovarian cancer	8.25e-07	1.35e-05	CbGpPWpGaD
